[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100429358":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":56,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Ulm","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Immunoadsorption",null,[12],"Device: Immunoadsorption",{"label":14,"type":10,"description":10,"interventionNames":15},"Plasma Exchange",[16],"Device: Plasma Exchange",[18,22],{"type":19,"name":9,"description":20,"armGroupLabels":21,"otherNames":10},"DEVICE","1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.",[9],{"type":19,"name":14,"description":23,"armGroupLabels":24,"otherNames":10},"1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.",[14],[26],{"name":27,"affiliation":5,"role":28},"Johannes Dorst, Prof","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":10,"email":33},"CONTACT","+49 731 177 5285","johannes.dorst@uni-ulm.de",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Department of Neurology, University of Ulm","RECRUITING","Ulm","Baden-Wurttemberg","89081","Germany","DE",{"type":44,"coordinates":45},"Point",[46,47],9.99155,48.39841,{"lat":47,"lon":46},[50,55],{"name":51,"role":31,"phone":52,"phoneExt":53,"email":54},"Albert C Ludolph, MD, Prof.","+49-731-177-","1200","albert.ludolph@rku.de",{"name":51,"role":28,"phone":10,"phoneExt":10,"email":10},{"type":28,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Albert Christian Ludolph, Prof.","Prof. Dr.",[60],{"name":61,"class":62},"DiaMed GmbH","INDUSTRY","100429358","immunoadsorption-versus-plasma-exchange-for-treatment-of-guillain-barr-syndrome-gbs-100429358",false,"NCT04871035","Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)","IPET-GBS","Inclusion Criteria:\n\n* Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)\n* age 18 years or above\n\nExclusion Criteria:\n\n* Clinical or laboratory (C-reactive protein 20 mg\u002Fl or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection\n* Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment\n* Other contraindications against immunoadsorption or plasma exchange","ALL","18 Years",{"count":73,"type":74},20,"ESTIMATED","OBSERVATIONAL","This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.",[78],"GBS","2026-04-30",{"date":81,"type":82},"2026-05-01","ACTUAL",{"date":84,"type":82},"2021-04-28",{"date":86,"type":74},"2027-09-01",{"name":5,"class":6},1]